CVS Looks Like a Drugstore. The Profit Lives in a PBM You've Never Walked Into.

Walk into a CVS for cough syrup and you've met the part of the company everyone thinks they understand: the aisles, the photo counter, the pharmacist behind the glass. It is also the part that matters least to the people who own the stock. The business that actually pays CVS Health's bills is one no customer ever walks into — a back-office machine called Caremark that decides which drugs your insurance covers, what they cost, and, increasingly, which pharmacy you're nudged to fill them at. In 2023, the segment that houses Caremark booked $186.8 billion in revenue out of $357.8 billion total — more than half the company.¹ The drugstore is the face. The PBM is the engine.

The official story is that CVS is a pharmacy chain that happens to own an insurer and a benefits manager. The truer story is the reverse: it is a pharmacy benefit manager that happens to own stores and an insurer — and the engine that holds the whole thing up is now the engine regulators are trying to dismantle.

The segment that shrank and stayed profitable anyway

Here is the move that tells you where the profit lives. In 2024, Caremark's segment had a bad year on the top line — revenue fell 7.1% to $173.6 billion, partly because Tyson Foods walked, handing its roughly 140,000 employees to a startup PBM instead.²⁸ Losing a client that size would gut most businesses. Caremark's adjusted operating income barely moved: down 0.9%, to about $7.2 billion.² A business that can shed revenue and keep its profit nearly flat is not selling volume. It is selling control — over formularies, over pricing spreads, over where the script gets filled — and control doesn't leave when a customer does.

Contrast that with the part of CVS everyone assumed was the safe bet: Aetna, the insurer. In the same year, Aetna's adjusted operating income collapsed 94.5%, from a real business to just $307 million, as Medicare Advantage members used far more care than priced for and the medical benefit ratio jumped to 92.1% from 86.2%.²³ CVS's full-year net income fell from $8.3 billion to $4.6 billion — a 45% drop almost entirely about Aetna, not Caremark.³ Read those two numbers together and the popular cross-subsidy story inverts. Caremark didn't bail out Aetna. Caremark's steadiness simply hid how badly Aetna was bleeding.

Why a 'middleman' is the most profitable seat in the room

A PBM is supposed to be a neutral negotiator: it sits between insurers, drugmakers, and pharmacies, extracts rebates, and passes savings along. Caremark is not neutral, and that is precisely the point. CVS owns the PBM, the specialty pharmacies, the mail-order operation, and the retail stores — so when Caremark designs a plan that steers a prescription to a CVS-affiliated pharmacy, the company collects on both ends of the same transaction. The FTC's first staff report found the six largest PBMs now manage nearly 95% of all U.S. prescriptions, and that pharmacies affiliated with the big three captured 68% of specialty drug dispensing revenue in 2023, up from 54% in 2016.⁵ That climb isn't a market discovering CVS pharmacies are better. It's a formulary doing the steering.

The mechanism gets blunter the closer you look. The FTC's January 2025 report found the big three PBMs — Caremark among them — marked up numerous specialty generic drugs dispensed at their own affiliated pharmacies by thousands of percent, generating over $7.3 billion in dispensing revenue above estimated acquisition costs from 2017 to 2022, plus roughly $1.4 billion more from spread pricing on those same drugs.⁶ Spread pricing is the quiet one: the PBM charges the plan one price, pays the pharmacy a lower one, and keeps the gap. When the PBM and the pharmacy are the same company, the 'gap' is just money moving from your left pocket to your right — and it shows up as profit either way.

The engine and the liability are the same machine

This is where the cross-subsidy story turns dangerous. The vertically integrated self-preferencing that makes Caremark the most reliable profit center at CVS is the exact behavior the FTC has spent two reports documenting and one lawsuit attacking. In September 2024 the agency filed an administrative action against Caremark, Express Scripts, and OptumRx over insulin rebating practices; as of early 2026 the case against Caremark remains pending, with CVS saying it is 'engaging in good faith negotiations' on a possible settlement.⁷ The thing that holds CVS up and the thing that could be forced to change are not two different stories. They are one machine, viewed from two sides.

Isn't a PBM just saving the system money?

The fair objection is that PBMs earn their keep: they negotiate rebates, build formularies, and manage drug spend for plans that couldn't do it alone. CVS makes exactly this case: CEO David Joyner stated on the company's Q4 2024 earnings call that multiple economists have estimated PBMs generate net value of more than $100 billion a year for the health-care system⁹ — though the figure stands on the company's own say-so, not independent verification. Some of the value is real. Aggregated buying power does extract concessions from drugmakers, and a well-run formulary does manage spend. But notice the shape of the FTC's evidence: the savings story and the self-dealing story coexist in the same drug. A PBM can negotiate a rebate on the front end and still mark up the dispensing by thousands of percent at a pharmacy it owns on the back end.⁶ The honest read isn't that Caremark adds nothing. It's that vertical integration lets it capture far more than the value it adds — and that the captured part is the part now under legal pressure. When Express Scripts settled its own FTC action on February 4, 2026, the agency required it to adopt fundamental changes to its business practices, including transparency mandates and limits on rebate-driven and spread pricing.¹⁰ Whatever Caremark eventually concedes, it will be conceding from the exact muscle that holds CVS up.

CVS spent a decade buying its way into every link of the prescription chain — the insurer, the benefits manager, the specialty pharmacy, the corner store — on the theory that owning the whole road meant collecting at every tollbooth on it. The theory worked: in a year when its insurer nearly fell over and its biggest PBM client walked out the door, the integrated machine still threw off $7.2 billion in dependable profit.² But the same integration that makes the money is the case file the FTC keeps building. CVS didn't just build a profit engine. It built a profit engine and a regulatory target out of the same parts — and it is now discovering that you cannot defend one without exposing the other.